-
K.
Serkies,
M.
Sinacki,
J.
Jassem
(2013)
The role of hormonal factors and endocrine therapy in ovarian cancer
Contemporary Oncology, 17
-
F.
Modugno,
R.
Laskey,
Ashlee
Smith,
C.
Andersen,
P.
Haluska,
S.
Oesterreich
(2012)
Hormone response in ovarian cancer: time to reconsider as a clinical target?
Endocrine-related cancer, 19 6
-
Peterson
Cm,
Zimniski
Sj
(1990)
A long-acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse
Obstetrics & Gynecology, 76
-
A.
Bowman,
H.
Gabra,
S.
Langdon,
A.
Lessells,
M.
Stewart,
A.
Young,
J.
Smyth
(2002)
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8 7
-
C.
Bossard,
M.
Busson,
D.
Vindrieux,
F.
Gaudin,
V.
Machelon,
M.
Brigitte,
Carine
Jacquard,
A.
Pillon,
P.
Balaguer,
K.
Balabanian,
G.
Lazennec
(2012)
Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer
PLoS ONE, 7
-
E.
Prossnitz,
M.
Barton
(2014)
Estrogen biology: New insights into GPER function and clinical opportunities
Molecular and Cellular Endocrinology, 389
-
R.
Finn,
J.
Crown,
I.
Láng,
K.
Boér,
I.
Bondarenko,
Sergey
Kulyk,
J.
Ettl,
Ravi
Patel,
T.
Pintér,
Marcus
Schmidt,
Y.
Shparyk,
A.
Thummala,
N.
Voytko,
C.
Fowst,
Xin
Huang,
Sindy
Kim,
S.
Randolph,
D.
Slamon
(2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
The Lancet. Oncology, 16 1
-
E.
Henić,
V.
Nosková,
G.
Høyer-Hansen,
S.
Hansson,
B.
Casslén
(2009)
Estradiol Attenuates EGF-Induced Rapid uPAR Mobilization and Cell Migration via the G-protein-Coupled Receptor 30 in Ovarian Cancer Cells
International Journal of Gynecologic Cancer, 19
-
M.
Miyazaki,
A.
Nagy,
A.
Schally,
N.
Lamharzi,
G.
Halmos,
K.
Szepesházi,
K.
Groot,
P.
Armatis
(1997)
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute, 89 23
-
K.
Hatch,
J.
Beecham,
J.
Blessing,
W.
Creasman
(1991)
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients
Cancer, 68
-
Peng
Lee,
D.
Rosen,
Changcheng
Zhu,
Elvio
Silva,
Jinsong
Liu
(2005)
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Gynecologic oncology, 96 3
-
J.
Malfetano,
J.
Beecham,
B.
Bundy,
K.
Hatch
(1993)
A Phase II Trial of Medroxyprogesterone Acetate in Epithelial Ovarian Cancers: A Gynecologic Oncology Group Study
American Journal of Clinical Oncology, 16
-
R.
Kothari,
P.
Argenta,
J.
Fowler,
J.
Carter,
W.
Shimp
(2010)
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.
Archive of oncology, 18 1-2
-
Y.
Yokoyama,
H.
Mizunuma
(2013)
Recurrent epithelial ovarian cancer and hormone therapy.
World journal of clinical cases, 1 6
-
S.
Wilailak,
C.
Vipupinyo,
V.
Suraseranivong,
K.
Chotivanich,
C.
Kietpeerakool,
Y.
Tanapat,
S.
Therasakvichya,
S.
Hamontri,
V.
Linasmita,
S.
Bunyapipat,
S.
Chindavijak,
K.
Ittiwisavakul,
N.
Khemapech,
P.
Suekwattana,
D.
Thanapprapasr,
P.
Lumbiganon
(2012)
Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control study
BJOG: An International Journal of Obstetrics & Gynaecology, 119
-
Emily
Fox,
Rebecca
Davis,
M.
Shupnik
(2008)
ERβ in breast cancer—Onlooker, passive player, or active protector?
Steroids, 73
-
Jennifer
Schultz,
L.
Petz,
A.
Nardulli
(2003)
Estrogen receptor α and Sp1 regulate progesterone receptor gene expression
Molecular and Cellular Endocrinology, 201
-
E.
Pujade-Lauraine,
F.
Hilpert,
B.
Weber,
A.
Reuss,
A.
Poveda,
G.
Kristensen,
R.
Sorio,
I.
Vergote,
P.
Witteveen,
A.
Bamias,
D.
Pereira,
P.
Wimberger,
A.
Oaknin,
M.
Mirza,
P.
Follana,
D.
Bollag,
I.
Ray-Coquard
(2014)
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 13
-
Jung-Hye
Choi,
Kyung-Tae
Lee,
P.
Leung
(2011)
Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth.
Carcinogenesis, 32 4
-
S.
Mabuchi,
M.
Ohmichi,
A.
Kimura,
Y.
Ikebuchi,
Koji
Hisamoto,
E.
Arimoto-Ishida,
Y.
Nishio,
Kazuhiro
Takahashi,
K.
Tasaka,
Y.
Murata
(2004)
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
Endocrinology, 145 3
-
M.
lenhard,
Lennerová
Tereza,
S.
Heublein,
N.
Ditsch,
I.
Himsl,
D.
Mayr,
K.
Friese,
U.
Jeschke
(2012)
Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival
BMC Cancer, 12
-
J.
Hamerlynck,
A.
Maskens,
C.
Mangioni,
M.
Burg,
J.
Wils,
J.
Vermorken,
N.
Rotmensz
(1985)
Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
Gynecologic oncology, 22 3
-
P.
Pujol,
J.
Rey,
P.
Nirdé,
P.
Roger,
M.
Gastaldi,
F.
Laffargue,
H.
Rochefort,
T.
Maudelonde
(1998)
Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis
Cancer Research, 58
-
M.
Stasenko,
M.
Plegue,
A.
Sciallis,
K.
McLean
(2015)
Clinical Response to Antiestrogen Therapy in Platinum-Resistant Ovarian Cancer Patients and the Role of Tumor Estrogen Receptor Expression Status
International Journal of Gynecologic Cancer, 25
-
K.
Chan,
Thomas
Leung,
D.
Chan,
N.
Wei,
G.
Lau,
Stephanie
Liu,
M.
Siu,
H.
Ngan
(2014)
Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
The Journal of endocrinology, 221 2
-
J.
Sparano,
R.
Gray,
D.
Makower,
K.
Pritchard,
K.
Albain,
D.
Hayes,
C.
Geyer,
E.
Dees,
E.
Perez,
J.
Olson,
J.
Zujewski,
T.
Lively,
S.
Badve,
T.
Saphner,
L.
Wagner,
T.
Whelan,
M.
Ellis,
S.
Paik,
W.
Wood,
P.
Ravdin,
M.
Keane,
H.
Moreno,
P.
Reddy,
T.
Goggins,
I.
Mayer,
A.
Brufsky,
D.
Toppmeyer,
V.
Kaklamani,
J.
Atkins,
J.
Berenberg,
G.
Sledge
(2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
The New England journal of medicine, 373 21
-
J.
Smyth,
C.
Gourley,
G.
Walker,
M.
Mackean,
A.
Stevenson,
Alistair
Williams,
A.
Nafussi,
T.
Rye,
R.
Rye,
M.
Stewart,
Janet
McCurdy,
M.
Mano,
N.
Reed,
T.
McMahon,
P.
Vasey,
H.
Gabra,
S.
Langdon
(2007)
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
Clinical Cancer Research, 13
-
T.
Rocereto,
T.
Rocereto,
H.
Saul,
H.
Saul,
J.
Aikins,
J.
Aikins,
James
Paulson,
James
Paulson
(2000)
Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Gynecologic oncology, 77 3
-
T.
Ignatov,
S.
Modl,
Maike
Thulig,
Christine
Weissenborn,
O.
Treeck,
O.
Ortmann,
AC
Zenclussen,
S.
Costa,
T.
Kalinski,
A.
Ignatov
(2013)
GPER-1 acts as a tumor suppressor in ovarian cancer
Journal of Ovarian Research, 6
-
T.
Rocereto,
W.
Brady,
M.
Shahin,
J.
Hoffman,
Laurie
Small,
J.
Rotmensch,
R.
Mannel
(2010)
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.
Gynecologic oncology, 116 3
-
L.
Cheung,
S.
Yung,
T.
Chan,
P.
Leung,
A.
Wong
(2013)
Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.
Molecular therapy : the journal of the American Society of Gene Therapy, 21 1
-
Claes
Tropé,
Christian
Marth,
J.
Kaern
(2000)
Tamoxifen in the treatment of recurrent ovarian carcinoma.
European journal of cancer, 36 Suppl 4
-
H.
Hirakawa,
Y.
Yokoyama,
H.
Yoshida,
H.
Mizunuma
(2014)
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
Journal of Ovarian Research, 7
-
D.
Roy,
N.
Angelini,
D.
Belsham
(1999)
Estrogen Directly Represses Gonadotropin-Releasing Hormone (GnRH) Gene Expression in Estrogen Receptor-α (ERα)- and ERβ-Expressing GT1-7 GnRH Neurons1.
Endocrinology, 140 11
-
M.
Schlumbrecht,
S.
Xie,
G.
Shipley,
D.
Urbauer,
R.
Broaddus
(2010)
Molecular Clustering Based on ERα and EIG121 Predicts Survival in High-Grade Serous Carcinoma of the Ovary/Peritoneum
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 24
-
Y.
Ng,
A.
Wolfe,
H.
Novaira,
S.
Radovick
(2009)
Estrogen regulation of gene expression in GnRH neurons
Molecular and Cellular Endocrinology, 303
-
B.
Kenealy,
K.
Keen,
E.
Terasawa
(2011)
Rapid action of estradiol in primate GnRH neurons: The role of estrogen receptor alpha and estrogen receptor beta
Steroids, 76
-
G.
Fleming
(2015)
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Obstetrical & Gynecological Survey
-
C.
Mangioni,
S.
Franceschi,
C.
Vecchia,
M.
D’Incalci
(1981)
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
Gynecologic oncology, 12 3
-
Tetsumi
Yano,
J.
Pinski,
G.
Halmos,
K.
Szepesházi,
K.
Groot,
A.
Schally
(1994)
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America, 91 15
-
Yan
Yan,
Huidi
Liu,
Hai-xia
Wen,
Xueli
Jiang,
Xuefeng
Cao,
Guangmei
Zhang,
Guo-yi
Liu
(2013)
The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells
Molecular and Cellular Biochemistry, 378
-
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
-
S.
Heublein,
D.
Mayr,
T.
Vrekoussis,
K.
Friese,
S.
Hofmann,
U.
Jeschke,
M.
lenhard
(2013)
The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients
PLoS ONE, 8
-
Clinical Medicine Insights: Oncology
-
A.
Burges,
A.
Brüning,
Christine
Dannenmann,
T.
Blankenstein,
U.
Jeschke,
N.
Shabani,
K.
Friese,
I.
Mylonas
(2010)
Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary
Archives of Gynecology and Obstetrics, 281
-
O.
Treeck,
G.
Pfeiler,
D.
Mitter,
C.
Lattrich,
G.
Piendl,
O.
Ortmann
(2007)
Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells
Journal of Endocrinology, 193
-
J.
Hasan,
N.
Ton,
S.
Mullamitha,
A.
Clamp,
A.
Mcneilly,
E.
Marshall,
Gordon
Jayson
(2005)
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
British Journal of Cancer, 93
-
G.
Irmer,
C.
Bürger,
R.
Müller,
O.
Ortmann,
Ursula
Peter,
S.
Kakar,
J.
Neill,
K.
Schulz,
G.
Emons
(1995)
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Cancer research, 55 4
-
I.
Ron,
N.
Wigler,
O.
Merimsky,
M.
Inbar,
S.
Chaitchik
(1995)
A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer.
Cancer investigation, 13 3
-
F.
Mungenast,
T.
Thalhammer
(2014)
Estrogen Biosynthesis and Action in Ovarian Cancer
Frontiers in Endocrinology, 5
-
C.
Papadimitriou,
S.
Markaki,
John
Siapkaras,
G.
Vlachos,
E.
Efstathiou,
I.
Grimani,
G.
Hamilos,
M.
Zorzou,
M.
Dimopoulos
(2004)
Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer
Oncology, 66
-
G.
Emons,
G.
Gorchev,
J.
Sehouli,
P.
Wimberger,
A.
Stähle,
L.
Hanker,
F.
Hilpert,
H.
Sindermann,
C.
Gründker,
P.
Harter
(2014)
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Gynecologic oncology, 133 3
-
G.
Walker,
K.
Macleod,
Alistair
Williams,
D.
Cameron,
J.
Smyth,
S.
Langdon
(2007)
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Gynecologic oncology, 106 3
-
S.
Symeonides,
C.
Gourley
(2015)
Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge
Frontiers in Oncology, 5
-
A.
Hałoń,
V.
Materna,
M.
Drąg-Zalesińska,
E.
Nowak-Markwitz,
Tserenchunt
Gansukh,
P.
Donizy,
M.
Spaczyński,
M.
Zabel,
M.
Dietel,
H.
Lage,
P.
Surowiak
(2011)
Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival
Pathology Oncology Research, 17
-
M.
Piccart,
G.
Hortobagyi,
M.
Campone,
K.
Pritchard,
F.
Lebrun,
Yoshinori
Ito,
S.
Noguchi,
Alejandra
Perez,
H.
Rugo,
I.
Deleu,
H.
Burris,
L.
Provencher,
P.
Neven,
M.
Gnant,
M.
Shtivelband,
C.
Wu,
Jenna
Fan,
W.
Feng,
T.
Taran,
J.
Baselga
(2014)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 12
-
R.
Chason,
Jung-Hoon
Kang,
S.
Gerkowicz,
M.
Dufau,
K.
Catt,
J.
Segars
(2015)
GnRH agonist reduces estrogen receptor dimerization in GT1-7 cells: Evidence for cross-talk between membrane-initiated estrogen and GnRH signaling
Molecular and Cellular Endocrinology, 404
-
P.
Wiernik,
E.
Greenwald,
H.
Ball,
J.
Young,
S.
Vogl
(1998)
High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884.
American journal of clinical oncology, 21 6
-
A.
Ciucci,
G.
Zannoni,
D.
Travaglia,
M.
Petrillo,
G.
Scambia,
D.
Gallo
(2014)
Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
Gynecologic oncology, 132 2
-
W.
Sieh,
M.
Köbel,
T.
Longacre,
D.
Bowtell,
A.
deFazio,
M.
Goodman,
E.
Høgdall,
S.
Deen,
N.
Wentzensen,
K.
Moysich,
J.
Brenton,
B.
Clarke,
U.
Menon,
C.
Gilks,
Andre
Kim,
J.
Madore,
S.
Fereday,
J.
George,
L.
Galletta,
G.
Lurie,
L.
Wilkens,
M.
Carney,
P.
Thompson,
R.
Matsuno,
S.
Kjær,
A.
Jensen,
C.
Høgdall,
K.
Kalli,
B.
Fridley,
G.
Keeney,
R.
Vierkant,
J.
Cunningham,
L.
Brinton,
Hannah
Yang,
M.
Sherman,
M.
García-Closas,
J.
Lissowska,
K.
Odunsi,
C.
Morrison,
S.
Lele,
W.
Bshara,
Lara
Sucheston,
M.
Jimenez-Linan,
K.
Driver,
J.
Alsop,
Marie
Mack,
V.
McGuire,
J.
Rothstein,
B.
Rosen,
M.
Bernardini,
H.
Mackay,
A.
Oza,
E.
Woźniak,
E.
Benjamin,
A.
Gentry-Maharaj,
S.
Gayther,
A.
Tinker,
Leah
Prentice,
C.
Chow,
M.
Anglesio,
S.
Johnatty,
G.
Chenevix-Trench,
A.
Whittemore,
P.
Pharoah,
E.
Goode,
D.
Huntsman,
S.
Ramus
(2013)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
The Lancet. Oncology, 14 9
-
A.
Hałoń,
E.
Nowak-Markwitz,
A.
Maciejczyk,
M.
Pudełko,
Tserenchunt
Gansukh,
Balázs
Győrffy,
P.
Donizy,
D.
Murawa,
R.
Matkowski,
M.
Spaczyński,
H.
Lage,
P.
Surowiak
(2011)
Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients.
Anticancer research, 31 2
-
J.
Geisler,
M.
Wiemann,
G.
Miller,
H.
Geisler
(1996)
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Gynecologic oncology, 60 3
-
S.
Saji,
Y.
Omoto,
C.
Shimizu,
M.
Warner,
Y.
Hayashi,
S.
Horiguchi,
Toru
Watanabe,
S.
Hayashi,
J.
Gustafsson,
M.
Toi
(2002)
Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Cancer research, 62 17
-
I.
Tkalia,
L.
Vorobyova,
A.
Grabovoy,
V.
Svintsitsky,
T.
Tarasova,
N.
Lukyanova,
I.
Todor,
V.
Chekhun
(2014)
Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Experimental oncology, 36 3
-
A.
O'Donnell,
K.
Macleod,
D.
Burns,
J.
Smyth,
S.
Langdon
(2005)
Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.
Endocrine-related cancer, 12 4
-
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen.
-
R.
Eeles,
J.
Morden,
M.
Gore,
J.
Mansi,
J.
Glees,
M.
Wenczl,
Christopher
Williams,
H.
Kitchener,
R.
Osborne,
D.
Guthrie,
P.
Harper,
J.
Bliss
(2015)
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 35
-
Yang
Li,
Yang
Li,
Wei
Hu,
S.
Fu,
Jin-Bo
Li,
Jihong
Liu,
J.
Kavanagh
(2007)
Aromatase inhibitors in ovarian cancer: is there a role?
International Journal of Gynecologic Cancer, 18
-
S.
Cunat,
P.
Hoffmann,
P.
Pujol
(2004)
Estrogens and epithelial ovarian cancer.
Gynecologic oncology, 94 1
-
Fiona
Simpkins,
A.
Garcia-Soto,
J.
Slingerland
(2013)
New insights on the role of hormonal therapy in ovarian cancer
Steroids, 78
-
A.
Pike,
A.
Brzozowski,
R.
Hubbard,
T.
Bonn,
A.
Thorsell,
O.
Engström,
J.
Ljunggren,
J.
Gustafsson,
M.
Carlquist
(1999)
Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
The EMBO Journal, 18
-
K.
Lau,
S.
Mok,
S.
Ho
(1999)
Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells
Proceedings of the National Academy of Sciences of the United States of America, 96
-
Cheng
Wang,
Xiangmin
Lv,
Chunbo
He,
Guohua
Hua,
M.
Tsai,
John
Davis
(2013)
The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization
Cell Death & Disease, 4
-
J.
Ribeiro,
R.
Freiman
(2014)
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer
The Journal of Steroid Biochemistry and Molecular Biology, 143
-
Caroline
Diep,
A.
Daniel,
L.
Mauro,
T.
Knutson,
C.
Lange
(2015)
Progesterone action in breast, uterine, and ovarian cancers.
Journal of molecular endocrinology, 54 2
-
S.
Saji,
Y.
Omoto,
C.
Shimizu,
M.
Warner,
Y.
Hayashi,
S.
Horiguchi,
Toru
Watanabe,
S.
Hayashi,
J.
Gustafsson,
M.
Toi
(2002)
Expression of Estrogen Receptor (ER) βcx Protein in ERα-positive Breast Cancer: Specific Correlation with Progesterone Receptor
Cancer Research, 62
-
P.
Völker,
C.
Gründker,
Oswald
Schmidt,
K.
Schulz,
G.
Emons
(2002)
Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
American journal of obstetrics and gynecology, 186 2
-
J.
Geisler,
E.
Buller,
K.
Manahan
(2008)
Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
European journal of gynaecological oncology, 29 2
-
E.
Høgdall,
L.
Christensen,
C.
Høgdall,
J.
Blaakaer,
S.
Gayther,
I.
Jacobs,
I.
Christensen,
S.
Kjaer
(2007)
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Oncology reports, 18 5
-
Joyce
Liu,
M.
Hirsch,
Hang
Lee,
U.
Matulonis
(2009)
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Gynecologic oncology, 115 3
-
P.
Argenta,
S.
Thomas,
P.
Judson,
L.
Downs,
M.
Geller,
L.
Carson,
A.
Jonson,
R.
Ghebre
(2009)
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer.
Gynecologic oncology, 113 2
-
S.
Wilkinson,
A.
Kucukmetin,
P.
Cross,
S.
Darby,
V.
Gnanapragasam,
A.
Calvert,
C.
Robson,
R.
Edmondson
(2008)
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer.
Human pathology, 39 8
-
D.
Bell,
A.
Berchuck,
M.
Birrer,
J.
Chien,
D.
Cramer,
F.
Dao,
R.
Dhir,
P.
Disaia,
H.
Gabra,
Pat
Glenn,
A.
Godwin,
J.
Gross,
L.
Hartmann,
M.
Huang,
D.
Huntsman,
M.
Iacocca,
M.
Imieliński,
S.
Kalloger,
B.
Karlan,
D.
Levine,
G.
Mills,
C.
Morrison,
D.
Mutch,
Narciso
Olvera,
S.
Orsulic,
K.
Park,
N.
Petrelli,
B.
Rabeno,
J.
Rader,
B.
Sikic,
K.
Smith-McCune,
A.
Sood,
D.
Bowtell,
R.
Penny,
J.
Testa,
K.
Chang,
H.
Dinh,
J.
Drummond,
G.
Fowler,
P.
Gunaratne,
A.
Hawes,
C.
Kovar,
L.
Lewis,
M.
Morgan,
I.
Newsham,
J.
Santibanez,
J.
Reid,
L.
Treviño,
Y.
Wu,
M.
Wang,
D.
Muzny,
D.
Wheeler,
R.
Gibbs,
G.
Getz,
M.
Lawrence,
K.
Cibulskis,
A.
Sivachenko,
C.
Sougnez,
Douglas
Voet,
Jane
Wilkinson,
Toby
Bloom,
K.
Ardlie,
T.
Fennell,
J.
Baldwin,
S.
Gabriel,
E.
Lander,
L.
Ding,
R.
Fulton,
D.
Koboldt,
M.
McLellan,
T.
Wylie,
Jason
Walker,
M.
O'Laughlin,
D.
Dooling,
L.
Fulton,
R.
Abbott,
N.
Dees,
Q.
Zhang,
C.
Kandoth,
M.
Wendl,
W.
Schierding,
D.
Shen,
C.
Harris,
H.
Schmidt,
Joelle
Kalicki,
K.
Delehaunty,
C.
Fronick,
Ryan
Demeter,
L.
Cook,
J.
Wallis,
L.
Lin,
V.
Magrini,
J.
Hodges,
James
Eldred,
S.
Smith,
C.
Pohl,
Fabio
Vandin,
Benjamin
Raphael,
G.
Weinstock,
E.
Mardis,
R.
Wilson,
M.
Meyerson,
W.
Winckler,
R.
Verhaak,
Suzie
Carter,
C.
Mermel,
G.
Saksena,
H.
Nguyen,
R.
Onofrio,
D.
Hubbard,
S.
Gupta,
A.
Crenshaw,
A.
Ramos,
L.
Chin,
A.
Protopopov,
Juinhua
Zhang,
T.
Kim,
I.
Perna,
Y.
Xiao,
Hailei
Zhang,
G.
Ren,
N.
Sathiamoorthy,
R.
Park,
E.
Lee,
P.
Park,
R.
Kucherlapati,
D.
Absher,
L.
Waite,
G.
Sherlock,
J.
Brooks,
Jun
Li,
Jin
Xu,
R.
Myers,
P.
Laird,
L.
Cope,
J.
Herman,
Hui
Shen,
D.
Weisenberger,
H.
Noushmehr,
F.
Pan,
T.
Triche,
B.
Berman,
D.
Berg,
J.
Buckley,
S.
Baylin,
P.
Spellman,
E.
Purdom,
P.
Neuvial,
H.
Bengtsson,
L.
Jakkula,
S.
Durinck,
J.
Han,
S.
Dorton,
H.
Marr,
Y.
Choi,
V.
Wang,
Ninghai
Wang,
J.
Ngai,
J.
Conboy,
B.
Parvin,
H.
Feiler,
T.
Speed,
J.
Gray,
N.
Socci,
Yanke
Liang,
B.
Taylor,
N.
Schultz,
L.
Borsu,
A.
Lash,
C.
Brennan,
A.
Viale,
C.
Sander,
M.
Ladanyi,
K.
Hoadley,
S.
Meng,
Y.
Du,
Yufeng
Shi,
Lulin
Li,
Y.
Turman,
D.
Zang,
E.
Helms,
S.
Balu,
X.
Zhou,
Jinhua
Wu,
M.
Topal,
D.
Hayes,
C.
Perou,
Jun
Zhang,
Chaowei
Wu,
S.
Shukla,
A.
Sivachenko,
R.
Jing,
Yueh-Feng
Liu,
M.
Noble,
H.
Carter,
D.
Kim,
R.
Karchin,
J.
Korkola,
Laura
Heiser,
R.
Cho,
Zhihao
Hu,
E.
Cerami,
A.
Olshen,
B.
Reva,
Yevgeniy
Antipin,
R.
Shen,
P.
Mankoo,
R.
Sheridan,
G.
Ciriello,
William
Chang,
J.
Bernanke,
D.
Haussler,
C.
Benz,
Joshua
Stuart,
S.
Benz,
J.
Sanborn,
Charles
Vaske,
Jiangyu
Zhu,
C.
Szeto,
G.
Scott,
C.
Yau,
M.
Wilkerson,
N.
Zhang,
R.
Akbani,
K.
Baggerly,
W.
Yung,
J.
Weinstein,
T.
Shelton,
D.
Grimm,
M.
Hatfield,
S.
Morris,
P.
Yena,
P.
Rhodes,
M.
Sherman,
J.
Paulauskis,
S.
Millis,
A.
Kahn,
J.
Greene,
R.
Sfeir,
M.
Jensen,
James
Chen,
J.
Whitmore,
S.
Alonso,
J.
Jordan,
A.
Chu,
Jinghui
Zhang,
A.
Barker,
C.
Compton,
G.
Eley,
M.
Ferguson,
P.
Fielding,
D.
Gerhard,
R.
Myles,
C.
Schaefer,
K.
Shaw,
J.
Vaught,
J.
Vockley,
P.
Good,
M.
Guyer,
B.
Ozenberger,
James
Peterson,
E.
Thomson
(2011)
Integrated Genomic Analyses of Ovarian Carcinoma
Nature, 474
-
F.
Duffaud,
M.
Burg,
M.
Namer,
I.
Vergote,
P.
Willemse,
W.
Huinink,
Jp.
Guastalla,
M.
Nooij,
Pierre
Kerbrat,
M.
Piccart,
Salvatore
Tumolo,
G.
Favalli,
N.
Vange,
A.
Lacave,
J.A
Wils,
T.
Splinter,
Nina
Einhorn,
K.
Roozendaal,
R.
Rosso,
Jb.
Vermorken
(2001)
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
Anti-Cancer Drugs, 12
-
Jennifer
Schultz,
L.
Petz,
A.
Nardulli
(2003)
Estrogen receptor alpha and Sp1 regulate progesterone receptor gene expression.
Molecular and cellular endocrinology, 201 1-2
-
H.
Poppel,
L.
Klotz
(2012)
Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists
International Journal of Urology, 19
-
Z.
Kolková,
Vera
Casslén,
E.
Henić,
S.
Ahmadi,
A.
Ehinger,
K.
Jirström,
B.
Casslén
(2012)
The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer
Journal of Ovarian Research, 5
-
N.
Vange,
S.
Greggi,
Curt
Burger,
Peter
Kenemans,
J.
Vermorken
(1995)
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Acta oncologica, 34 6
-
M.
Kruchten,
E.
Vries,
H.
Arts,
Neeltina
Jager,
A.
Bongaerts,
A.
Glaudemans,
H.
Hollema,
E.
Vries,
G.
Hospers,
A.
Reyners
(2014)
Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16α-18F-Fluoro-17β-Estradiol PET/CT
The Journal of Nuclear Medicine, 56
-
P.
Ramirez,
K.
Schmeler,
M.
Milam,
B.
Slomovitz,
Judith
Smith,
J.
Kavanagh,
M.
Deavers,
C.
Levenback,
R.
Coleman,
D.
Gershenson
(2008)
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Gynecologic oncology, 110 1
-
C.
Williams
(2001)
Tamoxifen for relapse of ovarian cancer.
The Cochrane database of systematic reviews, 1
-
C.
Gründker,
G.
Emons
Reproductive Biology and Endocrinology Role of Gonadotropin-releasing Hormone (gnrh) in Ovarian Cancer
-
G.
Emons,
O.
Ortmann,
Martin
Becker,
G.
Irmer,
B.
Springer,
R.
Laun,
F.
Hölzel,
K.
Schulz,
A.
Schally
(1993)
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
Cancer research, 53 22
-
J.
Ahlgren,
N.
Ellison,
R.
Gottlieb,
F.
Laluna,
J.
Lokich,
P.
Sinclair,
W.
Ueno,
G.
Wampler,
K.
Yeung,
D.
Alt
(1993)
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
-
C.
Gunderson,
K.
Moore
(2015)
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Future oncology, 11 5